RSA - kansikuva

Home > Risk-Sharing Agreements

Risk-Sharing Agreements

Comprehensive solutions for implementing risk-sharing models.

Contact us!

Confidential price agreements have become more widespread with regard to hospital medicines, while decisions on conditional reimbursement are becoming more established in the price and reimbursement processes of outpatient medicines.

Confidential agreements can be risk-sharing agreements (for example, pay for performance, conditional treatment continuation, or other contracts that reward the patient for the benefit of the treatment) or a method for sharing and managing uncertainty about the cost and effectiveness of medicines to the satisfaction of both parties. This will eventually make the medicine available to those patients who will benefit from it.

”Risk sharing agreements aim to solve the classic pharmaceutical sales dilemma of who bears the risk of effectiveness and cost effectiveness related to the purchasing and using of medicines.”

“We at Medaffcon execute risk-sharing agreements between the parties, ensuring that the agreements are operational and mutually beneficial. ”

In our service concept we:

  • determine the optimal method for evaluating the medicine and, if necessary, take care of the evaluation process to ensure a medicine’s rapid commissioning decision
  • design an optimal price agreement from the perspectives of both parties
  • when necessary, evaluate the cost-effectiveness of the selected model and the budget impact for both parties
  • are responsible for the agreement negotiations with hospitals, providing a neutral expert view on what sort of a model could be acceptable for both parties
  • organize the transfer of money and goods on a “turn-key” principle, regardless of whose distribution service is used (e.g. Tamro, Oriola, Magnum)

A successful risk-sharing agreement:

  • helps the parties to work in closer cooperation in the evaluation and implementation of a new form of treatment
  • helps all parties evaluate and set the value for a new or existing form of treatment in a more precise manner
  • ensures optimal treatment pricing to satisfy both parties, for example in cases where the effectiveness and benefits of new forms of treatments are still uncertain for the patient – and it enables the faster implementation and use of such treatment with a more sustainable pricing model
  • enables faster market access to a new form of treatment

Typical project phases

Risk sharing agreements - RSA - Project phases

Related articles

Jarmo Hahl

Jarmo Hahl

Managing Director

MSc (Economics)

+358 40 139 4001

Jarmo joined Medaffcon as a partner and CEO in 2010, having previously worked in various expert and management positions in pharma companies for eight years. Jarmo has a degree in economics and before entering the pharmaceutical industry, he held an office at the Turku School of Economics and also worked as a research fellow at Turku University Hospital.

Jarmo has strong expertise in new health technology innovations and how the demands and expectations of authorities, markets and customers are matched. He also brings to Medaffcon extensive experience in health economics and its applications in research and commercialization, as well as a broad understanding of the ever-changing operating environment.

“From an access point of view, the Finnish health technology market is constantly becoming more demanding and therefore also more attractive from my point of view. On the other hand, increasing demands to demonstrate the effectiveness and cost-effectiveness of healthcare are broadening the scope and opportunities for Medaffcon to be involved in the development of healthcare as a whole”.